Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir.
The use of tenofovir as part of a HAART regimen has been widely used in HIV-multi-experienced-patients because of its favourable resistance profile. Tenofovir is mainly eliminated by the kidneys and renal toxicity should be carefully monitored. We describe here the case of an HIV-infected patient, without a prior history of renal failure who developed nephrolithiasis and hydronephrosis after starting a tenofovir-containing HAART regimen.
Cicconi
P
P
Institute of Infectious and Tropical Diseases, Luigi Sacco Hospital, via G.B. Grassi 74, 20157 Milan, Italy.
Bongiovanni
M
M
Melzi
S
S
Tordato
F
F
d'Arminio Monforte
A
A
Bini
T
T
D000225:Adenine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006869:Hydronephrosis / Q000139:chemically induced*; D007669:Kidney Calculi / Q000139:chemically induced*; D008297:Male; D063065:Organophosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D000068698:Tenofovir
D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine